Q3 Earnings Estimate for Ardelyx Issued By Leerink Partnrs

Ardelyx, Inc. (NASDAQ:ARDX) – Analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Ardelyx in a research report issued on Thursday, February 20th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Leerink Partnrs also issued estimates for Ardelyx’s Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.40 EPS and FY2027 earnings at $1.00 EPS.

A number of other research firms have also weighed in on ARDX. HC Wainwright reaffirmed a “neutral” rating and set a $5.50 price objective on shares of Ardelyx in a research report on Friday. Piper Sandler raised their price target on Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Jefferies Financial Group lowered their price target on Ardelyx from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, January 2nd. Raymond James reissued a “strong-buy” rating and set a $13.00 price objective (down from $15.00) on shares of Ardelyx in a research report on Friday. Finally, Citigroup decreased their target price on shares of Ardelyx from $12.00 to $10.00 and set a “buy” rating for the company in a report on Monday, November 4th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $9.93.

Ardelyx Price Performance

Shares of NASDAQ ARDX opened at $5.13 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.87 and a current ratio of 4.03. The company has a 50 day simple moving average of $5.30 and a two-hundred day simple moving average of $5.63. Ardelyx has a fifty-two week low of $4.32 and a fifty-two week high of $9.83. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -32.06 and a beta of 0.85.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The business had revenue of $116.13 million during the quarter, compared to analyst estimates of $111.16 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 25.74%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Ardelyx during the 4th quarter valued at about $25,000. Newbridge Financial Services Group Inc. bought a new stake in Ardelyx during the fourth quarter valued at approximately $35,000. SBI Securities Co. Ltd. purchased a new stake in Ardelyx during the fourth quarter valued at approximately $41,000. Quarry LP bought a new position in Ardelyx in the fourth quarter worth approximately $51,000. Finally, Rehmann Capital Advisory Group bought a new position in Ardelyx in the fourth quarter worth approximately $51,000. 58.92% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, insider Laura A. Williams sold 4,941 shares of Ardelyx stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $5.62, for a total value of $27,768.42. Following the completion of the sale, the insider now owns 303,804 shares of the company’s stock, valued at approximately $1,707,378.48. The trade was a 1.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael Raab sold 25,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $5.26, for a total value of $131,500.00. Following the transaction, the chief executive officer now directly owns 1,150,385 shares in the company, valued at $6,051,025.10. The trade was a 2.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 141,408 shares of company stock worth $761,963. Company insiders own 5.90% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.